|
| 37467494 | Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. | Blood | 2023 |
| 36382911 | Carbon-11-Labeled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study. | American Journal of Roentgenology | 2023 |
| 35468618 | Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. | Blood advances | 2023 |
| 37601856 | Selinexor: Targeting a novel pathway in multiple myeloma. | | 2023 |
| 37778534 | Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. | | 2023 |
| 37471607 | Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. | | 2023 |
| 34531537 | Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. | Leukemia | 2022 |
| 35848842 | Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. | Blood Adv | 2022 |
| 35768410 | Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. | Blood Cancer Journal | 2022 |
| 36036363 | Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma. | Leukemia and Lymphoma | 2022 |
| 36058616 | Leaving Lytic Lesions-Is There New Role for Radiation in Multiple Myeloma in the CAR T Era? | Practical Radiation Oncology | 2022 |
| 36379208 | Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. | Cancer Cell | 2022 |
| 36316312 | Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. | Blood Cancer Journal | 2022 |
| 35660812 | Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. | N Engl J Med | 2022 |
| 34922860 | Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. | JACC: Cardiovascular Imaging | 2022 |
| 34972202 | Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. | Blood Adv | 2022 |
| 35027656 | Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. | Leukemia | 2022 |
| 35167125 | Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. | Cancer | 2022 |
| 35132679 | Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. | American Journal of Hematology | 2022 |
| 35114152 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. | Lancet Haematol | 2022 |
| 34702799 | Lifestyle considerations in multiple myeloma. | Blood Cancer J | 2021 |
| 34010042 | How to Treat High-Risk Myeloma at Diagnosis and Relapse. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2021 |
| 34163580 | The role of carfilzomib in relapsed/refractory multiple myeloma. | Therapeutic Advances in Hematology | 2021 |
| 33442665 | Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort. | JNCI Cancer Spectrum | 2021 |
| 34518309 | Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple Myeloma. | Clin Cancer Res | 2021 |
| 34675390 | Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. | Nat Cell Biol | 2021 |
| 34889430 | Minimal residual disease in multiple myeloma: why, when, where. | Hematology. American Society of Hematology. Education Program | 2021 |
| 31807884 | Quantitative [F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. | European Journal of Nuclear Medicine and Molecular Imaging | 2020 |
| 32417333 | Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? | JACC: Cardiovascular Imaging | 2020 |
| 32004107 | How We Approach Smoldering Multiple Myeloma. | Journal of Clinical Oncology | 2020 |
| 32094461 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. | Leukemia | 2020 |
| 30935459 | When acute kidney injury in the intensive care unit is not acute tubular necrosis: A case report of κ-light chain crystalline tubulopathy⿩. | Clinical Nephrology | 2019 |
| 30218303 | Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. | Skeletal Radiology | 2019 |
| 30279233 | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. | Clin Cancer Res | 2019 |
| 31503324 | Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. | Cancer | 2019 |
| 30954943 | Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body F-Florbetapir PET/CT. | | 2019 |
| 29315478 | Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. | British Journal of Haematology | 2018 |
| 32913989 | Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. | JCO Precision Oncology | 2018 |
| 29052442 | Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. | Future Oncology | 2018 |
| 30044692 | Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. | Journal of Clinical Oncology | 2018 |
| 30128502 | Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. | JAMA Oncology | 2018 |
| 29445026 | Panobinostat and Multiple Myeloma in 2018. | Oncologist | 2018 |
| 29749395 | Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. | Leukemia | 2018 |
| 29381435 | Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. | J Clin Oncol | 2018 |
| 29740809 | A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. | Br J Haematol | 2018 |
| 27890933 | Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. | Leukemia | 2017 |
| 28861842 | Myeloma and Bone Disease. | Current Osteoporosis Reports | 2017 |
| 28984867 | Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma. | Blood Cancer Journal | 2017 |
| 27913521 | Sequencing of nontransplant treatments in multiple myeloma patients with active disease. | Hematology. American Society of Hematology. Education Program | 2016 |
| 27344672 | Abdominal adipose tissue in MGUS and multiple myeloma. | Skeletal Radiol | 2016 |